Multicenter Clinical Performance Evaluation of the NeuMoDx CT/NG Assay 2.0
The NeuMoDx CT/NG Assay 2.0 demonstrated performance similar to currently US Food and Drug Administration-cleared assays, with the added choice of a moderate- (96-sample) or a high-throughput (288-sample) platform. The system therefore offers solutions to laboratories running lower volumes of testing that may obviate the need for outsourcing to larger reference laboratories.
Authors
- J. Philip Miller (ORCID: https://orcid.org/0000-0003-4568-6846)
- G Lazenby
- R. Lillis
- Douglas Young (ORCID: https://orcid.org/0000-0003-1203-3320)
- Barbara Van Der Pol (ORCID: https://orcid.org/0000-0003-3064-8564)
- Stephen B. Johnson (ORCID: https://orcid.org/0000-0002-6079-8419)
- Jürgen Ruth
- Victoria Louise Reid (ORCID: https://orcid.org/0000-0003-2804-8308)
- Ann Avery (ORCID: https://orcid.org/0000-0002-1953-8789)
- Stephen Young (ORCID: https://orcid.org/0000-0002-0376-6138)
- Christopher L. Emery (ORCID: https://orcid.org/0000-0002-2793-073X)
- Steven Chavoustie
- Lawrence R. Crane
- Steven N. Taylor
- G. E. Wall
Institutions
- Indiana University Health (US)
- MetroHealth (US)
- Planned Parenthood (US)
- Medical University of South Carolina (US)
- Henry Ford Health System (US)
- Nexen (Canada) (CA)
- University of Alabama at Birmingham (US)
- Northern California Research (US)
- Segal Institute for Clinical Research (US)
- Qiagen (Germany) (DE)
- Qiagen (United Kingdom) (GB)
- Applied Research Associates (United States) (US)
- MetroHealth Medical Center (US)
- Indiana University – Purdue University Indianapolis (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Woodward (United States) (US)
- Michigan State University (US)
Publication Details
- Journal
- Sexually Transmitted Diseases
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1097/olq.0000000000002075
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00